• 제목/요약/키워드: maximum tolerance dose

검색결과 31건 처리시간 0.022초

Bright Light Therapy in the Morning or at Mid-Day in the Treatment of Non-Seasonal Bipolar Depressive Episodes (LuBi): Study Protocol for a Dose Research Phase I / II Trial

  • Geoffroy, Pierre Alexis;El Abbassi, El Mountacer Billah;Maruani, Julia;Etain, Bruno;Lejoyeux, Michel;Amad, Ali;Courtet, Philippe;Dubertret, Caroline;Gorwood, Philip;Vaiva, Guillaume;Bellivier, Frank;Chevret, Sylvie
    • Psychiatry investigation
    • /
    • 제15권12호
    • /
    • pp.1188-1202
    • /
    • 2018
  • Objective This study protocol aims to determine, using a rigorous approach in patients with bipolar disorder (BD) and non-seasonal major depressive episode (MDE), the characteristics of bright light therapy (BLT) administration (duration, escalation, morning and mid-day exposures) depending on the tolerance (hypomanic symptoms). Methods Patients with BD I or II and treated by a mood stabilizer are eligible. After 1 week of placebo, patients are randomized between either morning or mid-day exposure for 10 weeks of active BLT with glasses using a dose escalation at 7.5, 10, 15, 30 and 45 minutes/day. A further follow-up visit is planned 6 months after inclusion. Patients will be included by cohorts of 3, with at least 3 days of delay between them, and 1 week between cohorts. If none meet a dose limiting toxicity (DLT; i.e hypomanic symptoms), the initiation dose of the next cohort will be increased. If one patient meet a DLT, an additionnal cohort will start at the same dose. If 2 or 3 patients meet a DLT, from the same cohort or from two cohorts at the same dose initiation, the maximum tolerated dose is defined. This dose escalation will also take into account DLTs observed during the intra-subject escalation on previous cohorts, with a "Target Ceiling Dose" defined if 2 DLTs occured at a dose. Discussion Using an innovative and more ergonomic device in the form of glasses, this study aims to better codify the use of BLT in BD to ensure a good initiation and tolerance.

비소세포 폐암의 제한된 각도를 이용한 세기변조와 용적변조회전 방사선치료계획의 폐 선량에 관한 연구 (A Study on lung dose of Intensity modulated and volumetric modulated arc therapy plans using restricted angle of Non-small cell lung cancer)

  • 염미숙;이우석;김대섭;백금문
    • 대한방사선치료학회지
    • /
    • 제26권1호
    • /
    • pp.21-28
    • /
    • 2014
  • 목 적 : 비소세포 폐암의 치료용적의 크기가 크거나 폐 용적이 작고, 몸의 정중선(Mid line)에 위치한 경우 척수의 허용선량을 고려한 방사선치료계획에서 폐 선량이 많아지게 되는데, 본 연구는 비소세포 폐암 환자의 3차원입체조형치료(Three dimensional conformal radiotherapy, 3D CRT), 제한된 각도를 이용한 세기변조방사선치료(Intensity modulated radiotherapy, IMRT)와 용적변조회전치료(Volumetric Modulated Arc therapy, VMAT) 치료계획을 각각 적용하여 전체 폐 선량을 비교 및 평가하고자 한다. 대상 및 방법 : TrueBeam STx($Varian^{TM}$, USA) 10 MV 에너지를 이용하여 4명의 환자에 대하여 3D CRT, 제한된 각도를 이용한 IMRT와 VMAT 치료계획을 세우고, 총 선량 66 Gy/30 Fx 처방하였을 때, 선량용적히스토그램(Dose Volume Histogram, DVH)을 이용하여 치료계획용적(Planning Target Volume, PTV), 전체 폐 그리고 척수에 들어가는 선량을 평가하였다. PTV에 대한 처방선량지수(Conformity Index, CI), 선량균질지수(Homogeneity index, HI), 처방선량포함지수(Paddick's Conformity Index, PCI)를 구하고, 폐의 30 Gy 용적($V_{30}$), $V_{20}$, $V_{10}$, $V_5$, 평균선량(Mean dose)을 평가하고, 척수의 최대선량 값을 평가하였다. 결 과 : PTV에 대한 CI, HI, PCI의 평균값은 각각 $0.944{\pm}0.009$, $1.106{\pm}0.027$, $1.084{\pm}0.016$으로 평가되었다. 전체 폐에 대한 첫 번째 환자의 $V_{20}$은 3D CRT, IMRT, VMAT 각각 30.7%, 20.2%. 21.2%, 두 번째 환자의 $V_{20}$은 33.0%, 29.2%. 31.5%, 세 번째 환자의 $V_{20}$은 51.3%, 34.3%. 36.9%, 네 번째 환자의 $V_{20}$은 56.9%, 33.7%. 40%로 제한된 각도를 이용한 IMRT 치료계획에서 가장 낮게 평가되었다. 척수에 대한 최대선량 값은 모두 허용선량 미만으로 평가되었다. 결 론 : 비소세포 폐암의 방사선치료계획에서 3D CRT와 비교했을 때, 제한된 각도를 이용한 IMRT나 VAMT을 이용하면 척수의 허용선량을 넘지 않으면서 폐 선량을 줄여줄 수 있는 치료계획을 세울 수 있었다. IMRT와 VAMT을 비교해보면 PTV의 선량포함과 척수선량을 고려했을 때 IMRT 치료계획에서 보다 좁은 각도를 이용한 치료계획이 가능하였고, 이는 폐 선량을 좀 더 줄여줄 수 있는 결과를 얻을 수 있었다.

새로운 퀴놀론계 항생제 LB20304a의 일반약리작용 (General Pharmacology of LB20304a, a New Quinolone Antibiotic)

  • 김희진;오정인;이창호
    • Biomolecules & Therapeutics
    • /
    • 제4권2호
    • /
    • pp.184-189
    • /
    • 1996
  • General pharmacological studies of LB20304a (a mesylate salt form of a new quinolone antibiotic LB20304 following oral administration of 300 mg/kg and 1000 mg/kg, almost maximum tolerance dose in mice and rat, respectively, were performed in terms of effects on general behaviour, central nervous system, gastrointestinal system, and blood coagulation system in mice and rats. With regards to general behaviour of mice, at oral dose of 300 mg/kg, LB20304a reduced muscle tone and locomotor activity. In terms of CNS, at oral treatment of 300 mg/kg, LB20304a showed some analgesic effects in mice, and oral dose of 1000 mg/kg caused drop in normal body temperature of rat, while it enhanced the pentylenetetrazole-induced clonic convulsion to tonic convulsion and/or death in mice at the doses of unto 300 mg/kg. In addition, LB20304a increased hexobarbital-induced sleeping time two and three times in mice at oral doses of 20 mg/kg and 300 mg/kg, respectively. Rota-rod and traction test in mice were not influenced by the dose of 300 mg/kg and 200 mg/kg, respectively. LB20304a reduced gastric secretion of rat at dose of 1000 mg/kg, and increased intestinal motility of mice at dose of 300 mg/kg. In rats, blood coagulation index, such as PT (prothrombin time) and aPTT (activated partial thromboplastin time) were not affected by the treatment of upto 1000 mg/kg of LB 20304a.

  • PDF

VERO system을 이용한 정위적 체부 방사선치료(SBRT)의 정확성 평가 (Assessment on Accuracy of Stereotactic Body Radiation therapy (SBRT) using VERO)

  • 이위용;김현진;윤나리;홍효지;김홍일;백승완
    • 대한방사선치료학회지
    • /
    • 제31권1호
    • /
    • pp.17-24
    • /
    • 2019
  • 목 적: 본 연구는 정위적체부방사선치료(Stereotactic Body Radiation Therapy, SBRT)용으로 개발된 선형가속기 VERO치료 시, 동중심점(Isocenter) 일치성과 점선량(Point dose)의 정확성을 평가하고자 한다. 대상 및 방법: 2018년 6월부터 12월까지 본원에서 시행한 SBRT 중 무작위로 선정한 10건의 치료계획으로 분석하였다. 선형가속기의 출력 안정성을 평가하기 위해 출력검출기 PTW-LinaCheck로 출력균일성(Output constancy)을 측정하였다. Laser와 kV imaging, MV beam의 기하학적 Isocenter의 정확성을 Isocenter Phantom(Tofu Phantom, Brain Lab)을 이용해 측정하고 평가하였다. 계획선량과 치료선량의 정확성 평가는 아크릴 팬텀($30{\times}30{\times}20cm$), 이온챔버 CC-01(IBA Dosimetry)와 Electrometer(IBA Dosimetry)를 이용해 선량을 측정하여 비교 및 분석하였다. 결 과: VERO의 출력균일성을 측정한 결과 0.66 %로 계산되었다. 기하학적 Isocenter 정확성은 Phantom 내부 Ball Isocenter의 오차 값을 분석한 결과 X축 방향에서는 최대 0.4 mm, 최소 0.0 mm로 평균값 0.28 mm였고, Y축 방향에서는 최대 -0.4 mm, 최소 0.0 mm로 평균값 -0.24 mm의 결과값을 얻었다. 치료계획선량과 실제측정선량을 비교 및 분석한 결과 치료계획선량과 실제측정선량의 오차는 최대 0.97 %, 최소 0.08%로 측정되었다. 결 론: 장비의 출력선량 평균은 0.66 %로 권고기준 ${\pm}3%$에 충족하고 매우 균일하게 출력되었다. 기하학적 Isocenter 정확성 평가에서 권고기준 ${\pm}1mm$ 이내로 환자 자세의 재현성이 매우 우수하다고 생각된다. 치료계획선량과 실제측정선량의 차이는 평균 0.52 %로 권고기준 3 % 이내로 충족하여 예측한 선량을 얻을 수 있음을 확인하였다. 이 실험들을 통해 VERO장비가 SBRT에 적합하고 우수한 치료 효과를 얻을 수 있을 것으로 사료된다.

표준 전자선 cone의 확장된 SSD에서의 선량평가 및 자체제작한 전자선 cone의 특성 (The Dosimetric evaluation of the standard electron cone for the extended cone for the extended SSD and The Dosimetric characteristics of the custom-made electron cone)

  • 정세영;정희영;김영범;권영호
    • 대한방사선치료학회지
    • /
    • 제11권1호
    • /
    • pp.73-78
    • /
    • 1999
  • In general, the patients of the head and neck cancer are treated with 4MV photon beam up to prescribed dose, but spinal cord should be excluded in the treatment field. When its absorbed dose is limited at the tolerance dose. In case of the patients who has the positive posterior neck nodes need a boost electron beam treatment to the prescribed dose. In that case, the anatomical structure of the neck and the physical structure of the standard electron cone interrupt to allow proper access to the disease site. Therefore, we extended treatment SSD for the remove of the those hindrances. In this study, we evaluated the dosimetric variation of the standard electron cone for the extended SSD, from 100cm to 120cm, 5 cm increment, and compare to the custom-made electron cone. As a result, the $\%$ depth dose, the point of maximum dose and the range of maximum were changed within the $2\%$. The penumbra width was increased from 1.0cm to 2.0cm. However, the dosimetric characteristics of the custom-made electron cone was very similar to that of the 100cm SSD standard electron cone and due to its characteristic of physical structure, patients didn't need re-positioning after photon beam treatment, therefore accurate treatment was possible, we conclude that the custom-made electron cone was very useful for the clinical practice.

  • PDF

방사선치료 시 자세확인시스템이 처방선량에 미치는 영향 (The Effect of Patients Positioning System on the Prescription Dose in Radiation Therapy)

  • 김정호;배석환
    • 대한방사선기술학회지:방사선기술과학
    • /
    • 제40권4호
    • /
    • pp.613-620
    • /
    • 2017
  • 방사선치료 시 치료계획 선량의 정확한 전달이 중요하다. 뿐만 아니라 정확한 자세 잡이도 필요하다. 하지만 정확한 자세 잡이를 위해서는 자세촬영을 실시하여야 하며 이에 따른 추가적인 방사선 피폭이 발생하게 된다. 이에 자세촬영 주기에 따른 선량분포의 변화를 분석하고자 한다. 팬텀 내 45개 지점에 대해 OSLD를 이용하여 6MV와 10MV 광자선, 그리고 온보드이미지촬영과 콘빔전산화단층촬영에 대한 선량을 측정하였다. 그리고 각 지점에 대한 자세확인촬영이 치료선량에 합산될 경우의 차이값을 비교하였다. 또한 차이값이 미국의학물리협회에서 권고하는 5%를 만족하는 촬영 주기를 제시하고자 하였다. 그 결과 6MV에서는 최소 45.27 cGy에서 최대 98.6 cGy, 10MV에서는 최소 53.34 cGy에서 최대 99.66 cGy, 온보드이미지촬영의 경우 최소 0.19 cGy에서 최대 2.64 cGy, 콘빔전산화단층촬영의 경우 최소 0.54 cGy에서 최대 17.18 cGy가 측정되었다. 치료선량에 대한 자세확인촬영 방사선량의 비율은 2차원 영상의 경우 치료 1회당 최대 3.49%, 3차원 영상의 경우 치료 1회당 최대 22.65%의 오차가 발생된다. 따라서 2차원 영상은 1일 1회, 3차원 영상은 1주 1회까지 허용된다. 향후 추가연구 시 실제 임상적용 시에는 환자자세촬영 종류의 병행에 대한 분리계산이 필요하리라 사료된다.

Planning and Dosimetric Study of Volumetric Modulated Arc Based Hypofractionated Stereotactic Radiotherapy for Acoustic Schwannoma - 6MV Flattening Filter Free Photon Beam

  • Swamy, Shanmugam Thirumalai;Radha, Chandrasekaran Anu;Arun, Gandhi;Kathirvel, Murugesan;Subramanian, Sai
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권12호
    • /
    • pp.5019-5024
    • /
    • 2015
  • Background: The purpose of this study was to assess the dosimetric and clinical feasibility of volumetric modulated arc based hypofractionated stereotactic radiotherapy (RapidArc) treatment for large acoustic schwannoma (AS >10cc). Materials and Methods: Ten AS patients were immobilized using BrainLab mask. They were subject to multimodality imaging (magnetic resonance and computed tomography) to contour target and organs at risk (brainstem and cochlea). Volumetric modulated arc therapy (VMAT) based stereotactic plans were optimized in Eclipse (V11) treatment planning system (TPS) using progressive resolution optimizer-III and final dose calculations were performed using analytical anisotropic algorithm with 1.5 mm grid resolution. All AS presented in this study were treated with VMAT based HSRT to a total dose of 25Gy in 5 fractions (5fractions/week). VMAT plan contains 2-4 non-coplanar arcs. Treatment planning was performed to achieve at least 99% of PTV volume (D99) receives 100% of prescription dose (25Gy), while dose to OAR's were kept below the tolerance limits. Dose-volume histograms (DVH) were analyzed to assess plan quality. Treatments were delivered using upgraded 6 MV un-flattened photon beam (FFF) from Clinac-iX machine. Extensive pretreatment quality assurance measurements were carried out to report on quality of delivery. Point dosimetry was performed using three different detectors, which includes CC13 ion-chamber, Exradin A14 ion-chamber and Exradin W1 plastic scintillator detector (PSD) which have measuring volume of $0.13cm^3$, $0.009cm^3$ and $0.002cm^3$ respectively. Results: Average PTV volume of AS was 11.3cc (${\pm}4.8$), and located in eloquent areas. VMAT plans provided complete PTV coverage with average conformity index of 1.06 (${\pm}0.05$). OAR's dose were kept below tolerance limit recommend by American Association of Physicist in Medicine task group-101(brainstem $V_{0.5cc}$ < 23Gy, cochlea maximum < 25Gy and Optic pathway <25Gy). PSD resulted in superior dosimetric accuracy compared with other two detectors (p=0.021 for PSD.

마황부자세신탕(麻黃附子細辛湯)의 마우스 단회 경구투여 독성 및 골수세포를 이용한 유전독성 평가 (Mouse Single Oral Dose Toxicity Test and Bone Marrow Micronucleus Test of Mahwangbujaseshin-tang Extracts)

  • 성익재;박미연;전우현;김종대
    • 동의생리병리학회지
    • /
    • 제23권5호
    • /
    • pp.1145-1153
    • /
    • 2009
  • The object of this study was to obtain acute information single oral dose toxicity of Mahwangbujaseshin-tang extracts, with mouse bone marrow cell micronucleus test for detecting possible genotoxicity. In order to observe the 50% lethal dose, approximate lethal dosage, maximum tolerance dosage and target organs, test articles were once orally administered to ICR mice at dose levels of 2000, 1000, 50 mg/kg according to the recommendation of KFDA Guidelines. The mortality and changes on body weight, clinical signs and gross observation were monitored during 14 days after dosing according to KFDA Guidelines with organ weights of 12 types of principle organs. In addition, after twice oral treatment of Mahwangbujaseshin-tang extracts 2000, 1000 and 500 mg/kg, we checked the changes on the number of MNPCE. We could not find any mortality, clinical signs, changes in the body weight and gross findings upto 2000 mg/kg treated group. The limited dosages in rodents except for increases of lymphoid organ weights and hypertrophy encounted as results from pharmacological effects of Mahwangbujaseshin-tang extracts, immune modulator effects with some sporadic accidental findings not toxicological signs. No evidence of increases of MNPCE numbers were also detected in all three different dosages of Mahwangbujaseshin-tang extracts treated mice. The results obtained in this study suggest that the LD50 and ALD of Mahwangbujaseshin-tang extracts in mice were considered as over 2000 mg/kg because no mortalities were detected upto 2000 mg/kg that was the highest dose recommended by KFDA and OECD. And the results of mouse bone marrow micronucleus test of Mahwangbujaseshin-tang extracts is negative results.

마황부자세신탕(麻黃附子細辛湯)의 마우스 단회 경구투여 독성 및 골수세포를 이용한 유전독성 평가 (Mouse Single Oral Dose Toxicity Test and Bone Marrow Micronucleus Test of Mahwangbujaseshin-tang Extracts)

  • 성익재;박미연;김종대
    • 동의생리병리학회지
    • /
    • 제24권1호
    • /
    • pp.124-133
    • /
    • 2010
  • The object of this study was to obtain acute information single oral dose toxicity of Mahwangbujaseshin-tang extracts, with mouse bone marrow cell micronucleus test for detecting possible genotoxicity. In order to observe the 50% lethal dose, approximate lethal dosage, maximum tolerance dosage and target organs, test articles were once orally administered to ICR mice at dose levels of 2000, 1000, 50 mg/kg according to the recommendation of KFDA Guidelines. The mortality and changes on body weight, clinical signs and gross observation were monitored during 14 days after dosing according to KFDA Guidelines with organ weights of 12 types of principle organs. In addition, after twice oral treatment of Mahwangbujaseshin-tang extracts 2000, 1000 and 500 mg/kg, we checked the changes on the number of MNPCE. We could not find any mortality, clinical signs, changes in the body weight and gross findings upto 2000 mg/kg treated group. The limited dosages in rodents except for increases of lymphoid organ weights and hypertrophy encounted as results from pharmacological effects of Mahwangbujaseshin-tang extracts, immune modulator effects with some sporadic accidental findings not toxicological signs. No evidence of increases of MNPCE numbers were also detected in all three different dosages of Mahwangbujaseshin-tang extracts treated mice. The results obtained in this study suggest that the LD50 and ALD of Mahwangbujaseshin-tang extracts in mice were considered as over 2000 mg/kg because no mortalities were detected upto 2000 mg/kg that was the highest dose recommended by KFDA and OECD. And the results of mouse bone marrow micronucleus test of Mahwangbujaseshin-tang extracts is negative results.

동일 기종 선형가속기간 8 MV 광자선에 대한 빔 매칭 정확도 평가 (Evaluation of Beam-Matching Accuracy for 8 MV Photon Beam between the Same Model Linear Accelerator)

  • 김연래;정진범;강성희
    • 대한방사선기술학회지:방사선기술과학
    • /
    • 제43권2호
    • /
    • pp.105-114
    • /
    • 2020
  • This study aimed to assess of beam-matching accuracy for an 8 MV beam between the same model linear accelerators(Linac) commissioned over two years. Two models were got the customer acceptance procedure(CAP) criteria. For commissioning data for beam-matched linacs, the percentage depth doses(PDDs), beam profiles, output factors, multi-leaf collimator(MLC) leaf transmission factors, and the dosimetric leaf gap(DLG) were compared. In addition, the accuracy of beam matching was verified at phantom and patient levels. At phantom level, the point doses specified in TG-53 and TG-119 were compared to evaluate the accuracy of beam modelling. At patient level, the dose volume histogram(DVH) parameters and the delivery accuracy are evaluated on volumetric modulated arc therapy(VMAT) plan for 40 patients that included 20 lung and 20 brain cases. Ionization depth curve and dose profiles obtained in CAP showed a good level for beam matching between both Linacs. The variations in commissioning beam data, such as PDDs, beam profiles, output factors, TF, and DLG were all less than 1%. For the treatment plans of brain tumor and lung cancer, the average and maximum differences in evaluated DVH parameters for the planning target volume(PTV) and the organs at risk(OARs) were within 0.30% and 1.30%. Furthermore, all gamma passing rates for both beam-matched Linacs were higher than 98% for the 2%/2 mm criteria and 99% for the 2%/3 mm criteria. The overall variations in the beam data, as well as tests at phantom and patient levels remains all within the tolerance (1% difference) of clinical acceptability between beam-matched Linacs. Thus, we found an excellent dosimetric agreement to 8 MV beam characteristics for the same model Linacs.